Literature DB >> 1200235

Yeast bezoar formation following gastric surgery.

Y Perttala, P Peltokallio, T Leiviskä, J Sipponen.   

Abstract

Yeast bezoar seems to be a relatively common late complication after various gastric operations. The incidence of bezoar depends decisively on the nature of the operation. Vagotomy in particular is conducive to the formation of a bezoar. Vagotomy + Billroth I resection proveded the most propitious conditions for the growth of yeast, for every one-half of the patients in this group developed a bezoar. Yeast bezoars usually appear within a year of the operation. The majority disappear during the first follow-up year, many without any therapy. However, in some cases the bezoar was a rather inconvenient late complication of gastric surgery and one that gave symptoms. It is difficult to draw any definite conclusions concerning the effect of therapy on the disappearance of the bezoar. We used gastric lavage and antimycotics as well as substances that increase gastric acidity. There is still no known method of preventing the formation of yeast bezoars. In the present consensus, a change in the acid conditions and disturbed gastric motility postoperatively are conducive to the formation of a bezoar.

Entities:  

Mesh:

Year:  1975        PMID: 1200235     DOI: 10.2214/ajr.125.2.365

Source DB:  PubMed          Journal:  Am J Roentgenol Radium Ther Nucl Med        ISSN: 0002-9580


  3 in total

1.  Cardiopulmonary complications in a patient with bezoar.

Authors:  Eulália Viveiros; Marta Moniz; Pedro Nunes; Catarina Silvestre
Journal:  BMJ Case Rep       Date:  2013-06-05

Review 2.  Acremonium species: a review of the etiological agents of emerging hyalohyphomycosis.

Authors:  Shukla Das; Rumpa Saha; Sajad Ahmad Dar; V G Ramachandran
Journal:  Mycopathologia       Date:  2010-06-25       Impact factor: 2.574

3.  Gastric mycosis following gastric resection and vagotomy.

Authors:  O Rehnberg; A Faxen; U Haglund; J Kewenter; B Stenquist; L Olbe
Journal:  Ann Surg       Date:  1982-07       Impact factor: 12.969

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.